Barclays analyst Balaji Prasad recommends using the pullback yesterday in shares of Coherus Biosciences as a buying opportunity. The analyst raised his price target for the stock to $31 from $30 and reiterates an Overweight rating on the name. Prasad had expected "strong" Udenyca trends throughout 2019 and says yesterday morning's preannouncement re-affirms his view. The negative stock reaction implies higher market expectations likely on extrapolating Symphony data, the analyst tells investors in a research note. However, he believes Coherus is a "fundamentally sound company delivering strong growth."